Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 67, Issue 10, Pages 848-853Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jclinpath-2014-202499
Keywords
-
Categories
Funding
- University of Western Sydney
- University of New South Wales
- Cancer Institute New South Wales for the CONCERT-Translational Cancer Research Unit
Ask authors/readers for more resources
Circulating tumour cells (CTCs) hold great potential as liquid biopsies to prognosticate disease and guide treatment in colorectal cancer. However, their emerging role in determining the molecular phenotype of tumour metastasis carries even more promising clinical use in the provision of comprehensive biomarker detection for targeted therapies and determination of drug resistance. The isolation of CTCs is technology dependent, and in the case of epithelial cell adhesion molecule-based platforms, the ability to detect cells that have undergone the epithelial to mesenchymal transition (EMT) is ineffective. CTCs displaying a mesenchymal phenotype are believed to have an increased metastatic potential. The rarity of CTCs provides another challenge in the enumeration of these cells. The future will likely involve the analysis of individual CTCs at any stage of the EMT in order to provide real-time phenotypic and molecular snapshots capable of tracking the dynamic evolution of tumour progression over time.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available